BIOLIFE SOLUTIONS INC

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

BLFS$38.61+3.5%Stored close · as of Oct 5, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,
(In thousands, except per share and share data)	2025	2024
Assets
Current assets:
Cash and cash equivalents	$33,038	$91,538
Available-for-sale securities, current portion	55,889	9,198
Accounts receivable, trade, net of allowance for credit losses of $22 and $152 as of December 31, 2025 and December 31, 2024, respectively	7,953	8,476
Inventories	30,155	29,013
Prepaid expenses and other current assets	9,526	5,952
Current assets, discontinued operations	—	4,584
Total current assets	136,561	148,761
Property and equipment, net	14,713	5,974
Operating lease right-of-use assets, net	7,466	10,553
Other assets	3,050	373
Available-for-sale securities, long term	31,250	4,628
Equity investments	—	995
Intangible assets, net	4,257	5,565
Goodwill	208,587	208,587
Long-term assets, discontinued operations	—	14,051
Total assets	$405,884	$399,487
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable	$1,486	$3,360
Accrued expenses and other current liabilities	11,974	12,123
Sales taxes payable	2,279	4,233
Lease liabilities, operating, current portion	2,243	1,459
Debt, current portion	4,997	10,943
Current liabilities, discontinued operations	—	616
Total current liabilities	22,979	32,734
Lease liabilities, operating, long-term	10,657	12,645
Debt, long-term	—	4,997
Deferred tax liabilities	189	124
Other long-term liabilities	171	—
Long-term liabilities, discontinued operations	—	78
Total liabilities	33,996	50,578
Commitments and contingencies (Note 11)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of December 31, 2025 and December 31, 2024	—	—

Common stock, $0.001 par value; 150,000,000 shares authorized, 48,198,928 and 46,906,765 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	48	47
Additional paid-in capital	711,404	683,939
Accumulated other comprehensive loss, net of taxes	132	24
Accumulated deficit	(339,696)	(335,101)
Total shareholders’ equity	371,888	348,909
Total liabilities and shareholders’ equity	$405,884	$399,487

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.